<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159897</url>
  </required_header>
  <id_info>
    <org_study_id>FIL-Rouge</org_study_id>
    <nct_id>NCT03159897</nct_id>
  </id_info>
  <brief_title>FIL Study on ABVD DD-DI as Upfront Therapy in HL.</brief_title>
  <official_title>A Randomized, Open-label, Multicenter, Phase III, 2-arm Study Comparing Efficacy and Tolerability of the Intensified Variant 'Dose-dense/Dose-intense ABVD' (ABVD DD-DI) With an Interim PET Response-adapted ABVD Program as Upfront Therapy in Advanced-stage Classical Hodgkin Lymphoma (HL).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FIL-Rouge is a randomized, open-label, multicenter, phase III, 2-arm study. The primary
      objective is to compare efficacy and tolerability of the intensified variant
      'dose-dense/dose-intense ABVD' (ABVD DD-DI) with an interim PET response-adapted ABVD program
      as upfront therapy in advanced-stage classical Hodgkin Lymphoma (HL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is devoted to patients affected with advanced stage (IIB-IV) Hodgkin Lymphoma.

      The study aims to compare the efficacy of two alternative ABVD-based strategies, the first
      one (Comparator arm) based on a PET-2-adaptation, the second (Experimental arm) relying on a
      straight dose- and time-intensified schedule, devoid of any PET-adaptation.

      In the Comparator arm, the patients will receive two courses of standard ABVD (ABVD-28).
      Those with a PET-2 negative scan (Deauville Score 1-3) will proceed with additional 4 ABVD
      courses while those with a PET-2-positive scan (Deauville score 4-5) will be diverted towards
      a deferred intensification with either escalated BEACOPP or HDT plus ASCR , according to the
      preference of the Center.

      In the Experimental arm, patients are treated with three cycles of a dose-dense/dose-intense
      ABVD (ABVD DD-DI) [e.g. a modified ABVD including the single escalation of doxorubicin to 35
      mg/m2 (70 mg/m2 per cycle) and a three-weekly recycle time for all drugs (e.g. administration
      of all 4 drugs at days 1 and 11 of each cycle)]. Those with a progressive disease or
      non-responder patients according to PET/CT imaging at interim evaluation (after cycle 3) as
      categorized with Lugano 2014 Classification will be diverted to salvage strategies. The other
      patients will receive one additional course of ABVD DD-DI followed by two courses of
      dose-dense three-weekly ABVD (ABVD DD) (e.g. administration of all four drugs at days 1 and
      11 of each cycle at the conventional doses, including doxorubicin at 25 mg/m2).

      In the Comparator arm, consolidation radiotherapy is planned on initial bulky disease sites
      even if PET negative (DS 1-2) (30 Gy), in patients with PET-negative (DS 3) rests (30 Gy) and
      in patients with a PET-positive rests (DS 4-5) (36 Gy) even if the residual lesion is not in
      a bulky lesion. In the Experimental arm, consolidation radiotherapy will be delivered only to
      rests at treatment completion, without intentional consolidation radiotherapy on the initial
      bulky, more specifically, in patients with DS3 rests (30 Gy) and in patients with a
      PET-positive rests (DS 4-5) (36 Gy) even if the residual lesion is not in a bulky lesion.

      Blinded independent central reviewing for PET imaging will supervise response categorization
      at interim and final PET/CT evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study aims to compare the efficacy of two alternative ABVD-based strategies, the first one (Comparator arm) based on a PET-2-adaptation, the second (Experimental arm) relying on a straight dose- and time-intensified schedule, devoid of any PET-adaptation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>PFS is defined as the interval elapsing from randomization until lymphoma progression or death as a result of any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate (CR rate)</measure>
    <time_frame>2 months and 6 months</time_frame>
    <description>CR rate is defined as the proportion of patients achieving a CR after 2 months of chemotherapy (interim) and at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET/CT response rate</measure>
    <time_frame>after 2 months of chemotherapy</time_frame>
    <description>PET/CT response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>3 years</time_frame>
    <description>EFS will be measured from the time from entry onto a study to any treatment failure including disease progression, or discontinuation of treatment for any reason (e.g., disease progression, toxicity, patient preference, initiation of new treatment lacking documented progression, or death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>3 years</time_frame>
    <description>DFS will be measured from the time of occurrence of disease-free state or attainment of a CR to disease recurrence or death as a result of lymphoma or acute toxicity of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>OS is defined as the time from entry onto the clinical trial until death as a result of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>6 months for acute toxicity and 5 years for late toxicity</time_frame>
    <description>Acute severe toxicity, acute and delayed pulmonary toxicity, acute and delayed cardiac toxicity. Late toxicity and second malignancies.
The severity of the toxicities will be classified according to definitions of Common Terminology Criteria for Adverse Event (CTCAE) version 4.3. It will be determined by the incidence of severe, life- threatening (CTCAE grade 3, 4 and 5) and/or serious adverse events (Infusion-related reactions).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>36 months</time_frame>
    <description>QoL will be measured at the baseline, the end of therapy and during follow-up through the EORTC QLQ-C30 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness analyses</measure>
    <time_frame>36 months</time_frame>
    <description>Cost-effectiveness analyses. ICER will be calculated by dividing the difference in mean total costs arms by the difference in the mean effects. The ICER will be calculated for the principal clinical effect measures of the trial. (i.e. PFS) and for QALYs. QALYs will be calculated multiplying the amount of time a patient spent in a particular health state by the utilities estimated using the EQ-5D questionnaires</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Comparator arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 2 courses of standard ABVD (ABVD-28, d1, d15, cycles of 28 days) and then proceed to interim PET/CT evaluation. Those with a PET-2-negative scan (score 1-3 on 5PS) will continue with additional 4 ABVD courses while those with a PET-2-positive (score 4-5) scan will be diverted towards an intensification phase with either escalated BEACOPP or HDT plus ASCR, according to the preference of the centre. Upon completion of treatment, patients will be categorized for response (Lugano2014) by comparing actual PET/CT imaging with baseline, whether 6 ABVD cycles or ABVDx2 + intensification phase with BEACOPP or HDT/ASCR. A salvage rescue program will be planned for patients with Stable (&lt;PR) or Progressive Disease. 30 Gy Involved Site Radiotherapy (ISRT) will be delivered as consolidation treatment on initial bulky site(s) and 30-36 on focal PET rests scoring â‰¥ 3 on 5PS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-dense and dose-intense ABVD regimen (ABVD DD-DI: intercycle 21 days, d1, d11; doxorubicin 35 mg/m2 DD 1 and 11) is given in cycles 1 to 4 and dose-dense ABVD (ABVD DD: intercycle 21 days, D1 and D11; conventional doxorubicin dose, e.g. 25 mg/m2 DD 1 and 11) is given as cycles 5 and 6). The treatment is not PET-adapted, and only patients with no response or progressive disease at interim FDG-PET as defined by the Lugano Classification (e.g., score 4 or 5 on 5PS with no significant change or with increased uptake matched with baseline and/or new FDG-avid foci consistent with lymphoma) will be diverted to salvage therapy. 30-36 Gy ISRT will be delivered as consolidation treatment on focal PET rests scoring â‰¥3 on 5PS at the end of ABVD DD-DI. No intentional consolidation radiotherapy on the initial bulky area(s) is scheduled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Comparator arm: cycle 1-2 (and eventually 3-6): 25 mg/m2 i.v. days 1,15. Experimental arm: Cycles 1 to 4: 35 mg/m2 i.v. days 1,11. Cycles 5 and 6: 25 mg/m2 i.v. days 1,11.</description>
    <arm_group_label>Comparator arm</arm_group_label>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin</intervention_name>
    <description>Bleomicina Comparator arm: cycle 1-2 (and eventually 3-6): 10,000 units/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 10,000 units/m2 i.v. days 1,11. Cycles 5 and 6: 10,000 units/m2 i.v. days 1,11.</description>
    <arm_group_label>Comparator arm</arm_group_label>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <description>Vinblastina Comparator arm: cycle 1-2 (and eventually 3-6): 6 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 6 mg/m2 i.v. days 1,11. Cycles 5 and 6: 6 mg/m2 i.v. days 1,11.</description>
    <arm_group_label>Comparator arm</arm_group_label>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>Dacarbazina Comparator arm: cycle 1-2 (and eventually 3-6): 375 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 375 mg/m2 i.v. days 1,11. Cycles 5 and 6: 375 mg/m2 i.v. days 1,11.</description>
    <arm_group_label>Comparator arm</arm_group_label>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed classical HL

          -  Previously untreated disease

          -  Age 18-60 years

          -  Ann Arbor stage IIB with extranodal involvement and/or mediastinal bulk, III and IV
             (Appendix A)

          -  At least one target PET-avid bidimensionally assessable lesion

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) â‰¤2 (Appendix B)

          -  Adequate organ and marrow function as defined below: absolute neutrophil count &gt;1,0
             x109/L, platelets &gt;75 x109/L

          -  Total bilirubin &lt;2 mg/dl without a pattern consistent with Gilbert's syndrome

          -  Aspartate Transaminase and Alanine Transaminase (AST/ALT) &lt;3 X institutional Upper
             Limits of Normality (ULN)

          -  Creatinine within normal institutional limits or creatinine clearance &gt;50 mL/min/1.73
             m2 (Appendix C)

          -  Females of childbearing must have a negative pregnancy test at medical supervision
             even if had been using effective contraception

          -  Life expectancy &gt; 6 months

          -  Able to adhere to the study visit schedule and other protocol requirements

          -  Sign (or their legally acceptable representatives must sign) an informed consent
             document indicating that they understand the purpose of and procedures required for
             the study and are willing to participate in the study.

          -  Access to PET-CT scans facilities qualified by FIL

        Exclusion Criteria:

          -  Nodular Lymphocyte Predominant HL

          -  Ann Arbor stage IIB without extranodal involvement and/or mediastinal bulky

          -  Prior chemotherapy or radiation therapy

          -  Pregnant or lactating females

          -  Known hypertension (as defined by 2013 European Societies of Hypertension and
             Cardiology (ESH/ESC) guidelines [71], cardiac arrhythmia, conduction abnormalities,
             ischemic cardiopathy, left ventricular hypertrophy or left ventricular ejection
             fraction (LVEF) â‰¤50% at echocardiography.

          -  Abnormal QTc interval prolonged (&gt;450 msec in males; &gt;470 msec in women)

          -  Diffusion lung capacity for CO (DLCO) and/or forced expiratory volume in the 1st
             second (FEV1) tests &lt;50% of predicted

          -  Known cerebral or meningeal disease (HL or any other etiology)

          -  Prior history of malignancies unless the patient has been free of the disease for five
             years. Exceptions include the following: basal cells carcinoma of the skin, squamous
             cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the
             breast and prostate cancer with TNM stage of T1a or T1b

          -  Uncontrolled infectious disease

          -  Human immunodeficiency virus (HIV) positivity or active infectious A, B or C
             hepatitis. HBsAg-negative patients with anti-HBc antibody and can be enrolled provided
             that Hepatitis B Virus (HBV)-DNA are negative and that antiviral treatment with
             nucleos(t)ide analogs is provided

          -  Uncompensated diabetes

          -  Refusal of adequate contraception

          -  Any medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Pinto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Napoli</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marina Cesaretti</last_name>
    <phone>+0039 059 4223165</phone>
    <email>mcesaretti@filinf.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elena Borgo</last_name>
    <phone>00390131206288</phone>
    <email>eborgo@filinf.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C. Ematologia</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia Salvi, MD</last_name>
      <email>flaviasalvi@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Flavia Salvi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale C.e G. Mazzoni -U.O.C. di Ematologia</name>
      <address>
        <city>Ascoli Piceno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Piero Galieni, MD</last_name>
      <email>piero.galieni@sanita.marche.it</email>
    </contact>
    <investigator>
      <last_name>Piero Galieni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S.Giuseppe Moscati -S.C. Ematologia e Trapianto emopoietico</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fausto Palmieri</last_name>
      <email>fausto.palmieri@alice.it</email>
    </contact>
    <investigator>
      <last_name>Fausto Palmieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Riferimento Oncologico - S.O.C. Oncologia Medica A</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Spina, MD</last_name>
      <email>mspina@cro.it</email>
    </contact>
    <investigator>
      <last_name>Michele Spina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Consorziale - U.O. Ematologia con Trapianto</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorgina Specchia, MD</last_name>
      <email>giorgina.specchia@uniba.it</email>
    </contact>
    <investigator>
      <last_name>Giorgina Specchia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Tumori Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Attilio Guarini, MD</last_name>
      <email>attilioguarini@oncologico.bari.it</email>
    </contact>
    <investigator>
      <last_name>Attilio Guarini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Monsignor Raffaele Dimiccoli&quot; - Ematologia</name>
      <address>
        <city>Barletta</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <email>giuseppetarantini0@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.R.N. Gaetano Rummo - DH Ematologico</name>
      <address>
        <city>Benevento</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Vallone</last_name>
      <email>rbtvallone@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Roberto Vallone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Degli Infermi - S.C. Oncologia</name>
      <address>
        <city>Biella</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annarita Conconi, MD</last_name>
      <email>annarita.conconi@aslbi.piemonte.it</email>
    </contact>
    <investigator>
      <last_name>Annarita Conconi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Orsola-Malpighi - Istituto di Ematologia &quot;Seragnoli&quot;</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pier Luigi Zinzani, MD</last_name>
      <email>pierluigi.zinzani@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Pier Luigi Zinzani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili di Brescia - Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Re, MD</last_name>
      <email>alessandro.re@asst-spedalicivili.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Re, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Antonio Perrino - Ematologia</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Maria Melpignano, MD</last_name>
      <email>angelamelpignano@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Angela Maria Melpignano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Businco - Ematologia</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefania Massidda, MD</last_name>
      <email>smassidda@email.it</email>
    </contact>
    <investigator>
      <last_name>Stefania Massidda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  Cattolica - Ematologia</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Storti, MD</last_name>
      <email>sergio.storti@unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Sergio Storti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia - IRCCS - Ematologia</name>
      <address>
        <city>Candiolo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delia Rota Scalabrini, MD</last_name>
      <email>delia.rota@ircc.it</email>
    </contact>
    <investigator>
      <last_name>Delia Rota Scalabrini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AORN S.Anna e S. Sebastiano - Oncoematologia</name>
      <address>
        <city>Caserta</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Camera, MD</last_name>
      <email>ancamera@unina.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Camera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Castelfranco Veneto - Ematologia</name>
      <address>
        <city>Castelfranco Veneto</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Sartori, MD</last_name>
      <email>roberto.sartori@aulss2.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Sartori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO pugliese De Lellis - Ospedale pugliese - SOC Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Molica, MD</last_name>
      <email>smolica@libero.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Molica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HSR Giglio - Oncologia</name>
      <address>
        <city>CefalÃ¹</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Mauro, MD</last_name>
      <email>orione7@inwind.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Mauro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luigi Rigacci, MD</last_name>
      <email>luigi.rigacci@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Luigi Rigacci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO S.Antonio Abate - Oncologia</name>
      <address>
        <city>Gallarate</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrizio Ciambelli, MD</last_name>
      <email>ciambelli@libero.it</email>
    </contact>
    <investigator>
      <last_name>Fabrizio Ciambelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti del Canavese</name>
      <address>
        <city>Ivrea</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Freilone, MD</last_name>
      <email>rfreilone@aslto4.piemonte.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Freilone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Vito Fazzi - Ematologia</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo, MD</last_name>
      <email>direnzo.ematolecce@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Madonna delle Grazie - Ematologia</name>
      <address>
        <city>Matera</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Fragasso, MD</last_name>
      <email>alberto.fragasso@libero.it</email>
    </contact>
    <investigator>
      <last_name>Alberto Fragasso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delia Cangini, MD</last_name>
      <email>delia.cangini@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Delia Cangini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU G. MARTINO - U.O.C. Ematologia</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppina Penna, MD</last_name>
      <email>giusypenna1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giuseppina Penna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedali Riuniti Papardo-Piemonte - S.C. Ematologia</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Donato Mannina, MD</last_name>
      <email>donamanni@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Donato Mannina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chiara Rusconi, MD</last_name>
      <email>chiara.rusconi@ospedaleniguarda.it</email>
    </contact>
    <investigator>
      <last_name>Chiara Rusconi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USLL13 - Dipartimento di Scienze Mediche UOC di Oncologia ed Ematologia Oncologica</name>
      <address>
        <city>Mirano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Bertoldero, MD</last_name>
      <email>giovanni.bertoldero@ulss13mirano.ven.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Bertoldero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Policlinico di Modena - Ematologia</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanna Leonardi, MD</last_name>
      <email>leonardi.giovanna@policlinico.mo.it</email>
    </contact>
    <investigator>
      <last_name>Giovanna Leonardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale A.Cardarelli - UnitÃ  complessa Ematologia TERE</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felicetto Ferrara, MD</last_name>
      <email>felicettoferrara@katamail.com</email>
    </contact>
    <investigator>
      <last_name>Felicetto Ferrara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Ematologia Oncologica</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Pinto, MD</last_name>
      <email>apinto.int.napoli@tin.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Pinto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P.O. San Gennaro ASL NA1 - Ematologia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Mastrullo, MD</last_name>
      <email>ematologia.ascalesi@aslnapoli1centro.it</email>
    </contact>
    <investigator>
      <last_name>Lucia Mastrullo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio ospedaliero &quot;A. TORTORA&quot;</name>
      <address>
        <city>Pagani</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonya De Lorenzo, MD</last_name>
      <email>s.delorenzo@aslsalerno.it</email>
    </contact>
    <investigator>
      <last_name>Sonya De Lorenzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Patti, MD</last_name>
      <email>k.patti@villasofia.it</email>
    </contact>
    <investigator>
      <last_name>Caterina Patti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Giaccone - Ematologia</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salvatrice Mancuso, MD</last_name>
      <email>salvatrice.mancuso@unipa.it</email>
    </contact>
    <investigator>
      <last_name>Salvatrice Mancuso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU di Parma - UO Ematologia e CTMO</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Re, MD</last_name>
      <email>fre@ao.pr.it</email>
    </contact>
    <investigator>
      <last_name>Francesca Re, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Matteo di Pavia - Div. di Ematologia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Bonfichi, MD</last_name>
      <email>bonfichi@smatteo.pv.it</email>
    </contact>
    <investigator>
      <last_name>Maurizio Bonfichi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO di Perugia - Ematologia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo Flenghi, MD</last_name>
      <email>flenghi@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Leonardo Flenghi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P.O. Spirito Santo di Pescara - UOS Dipartimentale - Centro di diagnosi e Terapia dei linfomi</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Angrilli, MD</last_name>
      <email>f.angrilli@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Angrilli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Guglielmo da Saliceto - U.O.Ematologia</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annalisa Arcari, MD</last_name>
      <email>a.arcari@ausl.pc.it</email>
    </contact>
    <investigator>
      <last_name>Annalisa Arcari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.R. &quot;San Carlo&quot; - U.O. Ematologia</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Cimminiello, MD</last_name>
      <email>miki-doc@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Michele Cimminiello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Bianchi Melacrino Morelli - Ematologia</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caterina Stelitano, MD</last_name>
      <email>caterinastelitano27@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Caterina Stelitano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS c/o CORE (II piano)</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Merli, MD</last_name>
      <email>merli.francesco@asmn.re.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Merli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi di Rimini</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Lia Molinari, MD</last_name>
      <email>annalia.molinari@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Anna Lia Molinari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS-Centro di riferimento oncologico - UO di ematologia e Trapianto Cellule Staminali</name>
      <address>
        <city>Rionero in Vulture</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Pietrantuono, MD</last_name>
      <email>ematologia45@alice.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Pietrantuono, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Sant'Andrea</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agostino Tafuri, MD</last_name>
      <email>agostino.tafuri@ospedalesantandrea.it</email>
    </contact>
    <investigator>
      <last_name>Agostino Tafuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I - UniversitÃ  &quot;La Sapienza&quot; - Istituto Ematologia -Dipartimento di Biotecnologie Cellulari ed Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Pulsoni, MD</last_name>
      <email>pulsoni@bce.uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Pulsoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-Medico - &quot;Area Ematologia Trapianto Cellule Staminali Medicina Trasfusionale e Terapia cellulare&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ombretta Annibali, MD</last_name>
      <email>o.annibali@unicampus.it</email>
    </contact>
    <investigator>
      <last_name>Ombretta Annibali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  Cattolica S. Cuore - Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Hohaus, MD</last_name>
      <email>stefan.hohaus@Unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Stefan Hohaus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas - U.O. Ematologia</name>
      <address>
        <city>Rozzano (MI)</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Santoro, MD</last_name>
      <email>armando.santoro@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Armando Santoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia e Trapianti A.O. San Giovanni di Dio e Ruggi D'Aragona - U.O. Ematologia</name>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmine Selleri, MD</last_name>
      <email>cselleri@unisa.it</email>
    </contact>
    <investigator>
      <last_name>Carmine Selleri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nuovo Ospedale Civile di Sassuolo - Day Hospital Oncologico</name>
      <address>
        <city>Sassuolo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Partesotti, MD</last_name>
      <email>g.partesotti@ospedalesassuolo.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Partesotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ. Perugia Sede Terni - Oncoematologia</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Marina Liberati, MD</last_name>
      <email>marina.liberati@unipg.it</email>
    </contact>
    <investigator>
      <last_name>Anna Marina Liberati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Federica Cavallo, MD</last_name>
      <email>f.cavallo@unito.it</email>
    </contact>
    <investigator>
      <last_name>Federica Cavallo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Citta della Salute e della Scienza di Torino - S.C.Ematologia</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Botto, MD</last_name>
      <email>bbotto@cittadellasalute.to.it</email>
    </contact>
    <investigator>
      <last_name>Barbara Botto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. C. Panico - U.O.C Ematologia e Trapianto</name>
      <address>
        <city>Tricase</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Pavone, MD</last_name>
      <email>salentoematologia@piafondazionepanico.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Pavone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. S. Maria della Misericordia di Udine - Clinica Ematologica</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Zaja, MD</last_name>
      <email>francesco.zaja@asuiud.sanita.fvg.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Zaja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced stage (IIB-IV)</keyword>
  <keyword>ABVD DD-DI</keyword>
  <keyword>PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

